18F-FES radiation dosimetry preliminary estimates for preclinical studies based on voxelized phantom

Andréa Vidal Ferreira; Ana Carolina Araujo Bispo; Christiane Silva Leite; Juliana Batista da Silva; Marcelo Mamede; Rodrigo Modesto Gadelha Gontijo; Bruno Melo Mendes

doi:10.15392/2319-0612.2022.2089

Autores/as

Andréa Vidal Ferreira Centro de Desenvolvimento da Tecnologia Nuclear CDTN/CNEN https://orcid.org/0000-0001-7698-4323
Ana Carolina Araujo Bispo Centro de Desenvolvimento da Tecnologia Nuclear https://orcid.org/0000-0002-1934-9881
Christiane Silva Leite Centro de Desenvolvimento da Tecnologia Nuclear https://orcid.org/0000-0003-3336-8912
Juliana Batista da Silva Centro de Desenvolvimento da Tecnologia Nuclear https://orcid.org/0000-0002-0794-1896
Marcelo Mamede Universidade Federal de Minas Gerais (UFMG) , https://orcid.org/0000-0001-5818-0954
Rodrigo Modesto Gadelha Gontijo Universidade Federal de Minas Gerais (UFMG) , https://orcid.org/0000-0001-6479-3087 (no autenticado)
Bruno Melo Mendes Centro de Desenvolvimento da Tecnologia Nuclear https://orcid.org/0000-0002-8914-8022

DOI:

https://doi.org/10.15392/2319-0612.2022.2089

Palabras clave:

radiation dosimetry,, 18F-FES, preclinical studies

Resumen

Small animals, such as mice, are used in radiopharmaceutical biodistribution studies and innumerous others preclinical investigations involving ionizing radiation. Longitudinal preclinical studies with five or more image procedures, involving radiopharmaceuticals injection and/or X-radiation, are not uncommon. However, a suitable dosimetric evaluation is not always available and, sometimes, absorbed doses in animal organs or tissues and their influence in experimental results were not appropriately taken into account. Accurate calculation of absorbed doses in mice organs are needed to evaluate potential radiobiological effects that may interfere with in vivo experiments. In this work, we perform a preliminary 16α-[¹⁸F]-fluoro-17β-estradiol (¹⁸F-FES) radiation dosimetry estimates for female mice. The obtained animal dosimetric results can be useful for evaluating animal doses during the design of longitudinal preclinical studies.

Descargas

Los datos de descarga aún no están disponibles.

Referencias

INCA – Instituto Nacional do Câncer José Alencar Gomes da Silva. Estimativa 2014: Incidência de Câncer no Brasil. Rio de Janeiro: INCA, 2014.

FLANAGAN, F. L et al., PET in Breast Cancer. Semin Nucl Med, v. 28, p. 290-302, 1998.

LINDEN, H. M. L et DEHDASHTI, F. Novel Methods and Tracers for Breast Cancer Imaging, Semin. Nuc. Med. v. 43, n. 4, p. 324-329 2013.

ALAM, I. S. et al., Radiopharmaceuticals as probes to characterize tumor tissue, Eur. J. Nuc. Med. Mol. Imag. v. 42, n. 4, p. 537-561, 2015.

SUDARARAJAN, L. et al., 18F-Fluoroestradiol, Semin Nucl Med, v. 37, n. 6, p. 470-476, 2007.

ORDINAS, H. E. et al., PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody, J. Immunother. Cancer, v. 1, n. 14, p. 1-11, 2013.

WANG, Y. et al., [18F]DPA-714 PET Imaging of AMD3100 Treatment in a Mouse Model of Stroke, Mol. Pharm., v. 11, p. 3463-3470, 2014.

VAHLE, A.K. et al., Multimodal imaging analysis of an orthotopic head and neck cancer mouse model and application of anti-CD137 tumor immune therapy, Head Neck, v. 38, n. 4, p. 542-529, 2016.

STELLAS, D. et al., Therapeutic Effects of an Anti-Myc Drug on Mouse Pancreatic Cancer, J. Natl. Cancer Inst., v. 106, n. 12, p. 1-8, 2014.

REX, K. et al., Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model, Nucl. Med. Biol., v. 40, n. 4, p. 458-463,2013.

POLLOK, K.,E. et al., In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography, J Oncol, v. 2009, Article ID 596560, 8 pages, doi:10.1155/2009/596560, 2009

S. Hu et al., Longitudinal PET Imaging of Doxorubicin-Induced Cell Death with 18F-Annexin V., Mol Imaging Biol, v. 14, p. 762-770, 2012

DUNCAN K. et al., 18F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib, Blood Cancer J, v. 3, p. 1-12, 2013.

WANG G. J. et CAI L.., Induction of Cell-Proliferation Hormesis and Cell-Survival Adaptive Response in Mouse Hematopoietic Cells by Whole-Body Low-Dose Radiation, Toxicol. Sci., v. 53, p. 369–376, 2000.

YANEZAWA M, Induction of radio-resistance by low dose X-irradiation Yakugaku Zasshi, v. 126, n. 10, p. 833–840, 2006.

MENDES, B. M. et al., Development of a mouse computational model for MCNPx based on Digimouse® images and dosimetric assays, Braz. J. Pharm. Sci., 2017; v. 53, n. 1, 2017

KINASE, S. et al., Computer Simulations for Internal Dosimetry Using Voxel Models, Radiat. Prot. Dosim, v. 146, n. 1-3, p. 191–194, 2011.

BISPO, A.C.A. et al., Development of a Female Mouse Computational Model Based on CT Images for Dosimetric Assays. In: http://repositorio.ipen.br/bitstream/handle/123456789/ 32876/28598.pdf?sequence=1&isAllowed=y; Accessed: 2022, July.

BISPO, A.C.A. et al., Synthesis and characterization of the radiopharmaceutical [18F]fluoroestradiol, Braz. J. Radiat. Sci., v. 09, n. 01A, p. 01-11, 2021

LOENING, A. M. and GAMBHIR, S. S. AMIDE: A Free Software Tool for Multimodality Medical Image Analysis. Mol. Imaging, v. 2, n. 3, p. 131–137, 2003

BOLCH, W. E. et al., MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature, J Nucl MED, v. 50, p. 477-84, 2009.

GOORLEY, J. T. et al., MCNP6 User’s Manual, Version 1.0, LA-CP-13-00634, Los Alamos National Laboratory, no. LA-CP-13-00634. p. 765, 2013.

ICRP, ICRP Publication 110: Adult Reference Computational Phantoms, Ann. ICRP, v. 39, n. 2, pp. 47–70, 2009.

ICRP, ICRP Publication 107: Nuclear decay data for dosimetric calculations, Ann. ICRP, vol. 38, no. 3, pp. 7–96, 2008.

DAHLMAN-WRIGHT, K et al., International Union of Pharmacology. LXIV. Estrogen Receptors. Pharmacol. Rev. vol.58, pp. 773–781, 2006.

NHI. National Cancer Institute. FES Documentation Page. [18F] FES Investigator's Brochure. In: https://imaging.cancer.gov/programs_resources/cancer-tracer-synthesis-resources/docs/ fes_ib_pdf.pdf. Accessed: 2022, July.